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ABSTRACT 
Metabolic alteration is not uncommon in patients with major mental illnesses (MMI) and adipokines are thought to play some 
roles. Presently, the link between adiposity, adipokines release and MMI is still poorly understood. This study was carried out to 
determine the possible impact of central adiposity and type of antipsychotic medication on plasma levels of adiponectin and 
resistin in patients with MMI. Plasma levels of adiponectin and resistin were determined in ninety adults comprising 65 patients 
with MMI and 25 apparently healthy individuals, who served as controls. Anthropometry and blood pressure (BP) of the study 
participants were taken using standard methods. Anthropometric indices, BP and plasma level of adiponectin, but not resistin, 
were significantly higher in patients with MMI compared with the controls. The median plasma adiponectin level was 
significantly higher in patients with depression compared with patients with schizophrenia and the controls. However, the median 
plasma levels of adiponectin and resistin were insignificantly higher in patients with central obesity compared with patients 
without central obesity and in patients on atypical drugs compared with patients on typical drugs. Also, there was no significant 
difference in the median plasma levels of adiponectin and resistin in patients on clozapine or olanzapine compared with those on 
risperidone. It could be concluded from this study that patients with MMI have elevated level of adiponectin which does not 
appear to be influenced by central adiposity and type of antipsychotic medication. 
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INTRODUCTION 
 
Adipose tissue, which was viewed as a reservoir for energy, 
continues to be an important organ involved in regulating lipid 
metabolism as well as other processes including host defense, 
inflammation and apoptosis (Liang and dong Ye, 2019). Its 
products , which could be hormones, cytokines and other 
inflammatory factors, play important roles in regulating 
systems within the body and are involved in the pathogenesis 
of numerous metabolic diseases (Bohler et al., 2010). 
 It is known that metabolic abnormalities are not 
uncommon in patients with major mental illnesses (MMI) 
(Akinlade et al., 2016) however, the mechanisms underlying 
the abnormalities are not completely understood. Sequel to the 
widely established link between adipokines and metabolic 
alteration in obesity and metabolic syndrome, metabolic 
alteration associated with MMI can also be potentially 
mediated by adipokines, among other factors including 
antipsychotic use, physical inactivity, obesity, psychological 
stress and genetic predisposition (Taylor and Macqueen, 2010, 
Expert-Committee, 2013).  
 One of the prominent and well-studied adipokines is 
adiponectin which is a 244-amino acid peptide produced by 
mature adipocytes. Adiponectin is involved in the aetiology of 
depression-related disorders (Wedrychowicz et al., 2014) and 
its level has been shown not to be low in patients with 
depression only but also in patients with schizophrenia and 
panic disorders (Cohn et al., 2006, Diniz et al., 2012, Unsal et 
al., 2012). Lehto et al. (2010) showed that the likelihood of 
depression increases with approximately 20% with each 
5μg/ml decrease in serum adiponectin. Furthermore, Liu et al. 
(2012) reported that adiponectin has antidepressant-like 
activity and its decreased level is associated with impaired 
glucocorticoid-mediated negative feedback on hypothalamic-
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pituitary-adrenal (HPA) axis. In patients with schizophrenia, 
Song et al. (2013) reported elevated adiponectin level in drug 
naïve, first episode schizophrenia patients with normal body 
weight. However, a meta-analysis by Bartoli et al. (2015) 
showed that patients with schizophrenia do not have lower 
adiponectin level, except those on clozapine and olanzapine, 
when compared with apparently healthy individuals. These 
reports show that the mechanisms involved in adipokine level 
alteration as well as its relation to the pathogenesis of 
schizophrenia need further research. 
 Another adipokine of significant importance in metabolic 
regulation is resistin. Despite the available reports on the 
association between resistin and insulin resistance (IR), the 
exact role it plays in the pathogenesis of manifestations of IR 
such as type 2 diabetes mellitus is still poorly understood 
(Jamaluddin et al., 2012). During inflammation, its level 
increases with increasing levels of mediators of inflammation 
thereby making it suitable in predicting severity of certain 
diseases (Reilly et al., 2005, Cherneva et al., 2013, 
Emamalipour et al., 2019). There has been conflicting reports 
on serum resistin levels in patients with major depressive 
disorder (MDD). Carvalho et al. (2014) reported lower resistin 
level in MDD compared with controls. Similarly, Weber-
Hamann et al. (2007) reported lower resistin level in patients 
remitting to anti-depressive treatment compared to non-
remitters. In contrast, Pan et al. (2008) reported that there is 
no association between depression and resistin. Although the 
exact role of resistin in the pathogenesis of bipolar disorder 
(BD) is not known, it is suggested to be involved in the 
pathogenesis of the disease (Wedrychowicz et al., 2014). 
Yumru et al. (2012) reported elevated resistin level in patients 
with BD compared with controls. Similarly, resistin level is 
shown to be elevated in patients with schizophrenia,this was 
attributed to its proinflammatory property (Klemettila et al., 
2017). 
 In order to provide information on the link between 
adiposity, adipokines, type of antipsychotic medication and 
mental disorders, this study was carried out to determine the 
plasma levels of adiponectin and resistin in patients with 
major mental illnesses. 
 
MATERIALS AND METHODS 
 
Selection of Study Participants: After obtaining an approval 
from the University of Ibadan/University College Hospital 
(UI/UCH) Joint Ethical Committee and written informed 
consent or assent from the participants, relatives or caregivers 
as appropriate, ninety adults comprising 65 patients with 
major mental illnesses (MMI) and 25 apparently healthy 
individuals were enrolled into this study. Participants with 
MMI were randomly selected from amongst the patients 
enrolled into our previous study (Akinlade et al., 2016). In 
brief, 124 adult patients with either schizophrenia, depression 
or bipolar were enrolled into a study on “metabolic alteration 
in major mental illnesses”. Out of this cohort, 90 patients with 
stable medical condition were carefully selected for this study.    
 
Diagnosis of Major Mental Illness (MMI): Diagnosis of 
MMI; schizophrenia, depression and bipolar disorder was 
made using the Structured Clinical Interview for DSM IV 
Axis I Disorder (SCID) version 2.0. The SCID is used as part 
of a normal assessment procedure to confirm a particular 
diagnosis or in research or screening as systematic evaluation 
of a whole range of medical states (Akinlade et al., 2016, 
2018).  
 
Measurement of Anthropometric Indices and blood 
sample collection: Anthropometric indices were measured 
using standard method (Akinlade et al., 2016). Venous blood 
samples were obtained from the study participants after an 
overnight fast (8 – 10 hours) and plasma obtained 
appropriately. Samples were kept at -200C until analyzed.  
 
Laboratory Analysis: Plasma levels of adiponectin and 
resistin were determined using ELISA (WKEA, China) 
following manufacturer’s instruction.  
 
Statistical Analysis 
Statistical analysis was done using ANOVA, Kruska Wallis, 
independent Student’s t-test and Mann Whitney U. P-values 




Table 1 shows the anthropometric indices, blood pressure and 
plasma levels of adiponectin and resistin in the study 
participants. The mean body weight, BMI, WC, HC, SBP and 
DBP were significantly higher in patients with MMI 
compared with the controls. Similarly, the median plasma 
level of adiponectin was significantly higher in patients with 
MMI compared with controls. However, the median plasma 
resistin levels were similar between the 2 groups. 
 
Table 1:  
Anthropometry, blood pressure and plasma adiponectin and resistin in patients with major mental illnesses (MMI) and controls 
Parameters MMI (n = 65) Controls (n = 25) P-value 
Height (m) 1.68 ± 0.10 1.69 ± 0.08 0.477 
Body weight (kg) 72.10 ± 15.23 64.52 ± 9.85 0.008* 
BMI (kg/m2) 25.64 ± 4.95 22.57 ± 3.20 0.005* 
WC (cm) 87.58 ± 13.52 78.28 ± 8.81 0.002* 
HC (cm) 99.23 ± 12.47 87.60 ± 6.92 0.000* 
WHR 0.89 ± 0.11 0.89 ± 0.07 0.977 
SBP (mmHg) 114.55 ± 13.53 104.60 ± 10.20 0.001* 
DBP (mmHg) 76.60 ± 11.62 69.20 ± 6.40 0.003* 
Adiponectin (mg/l) 1807.56 (1204.56 – 2557.85) 1106.63 (877.85 – 2072.73) 0.015* 
Resistin (μg/l) 17.29 (13.13 – 20.91) 19.37 (14.95 – 21.30) 0.194 
*Significant at P<0.05, BMI = Body mass index, WC = Waist circumference, HC = Hip circumference, WHR = Waist hip ratio, SBP = Systolic blood pressure, 
DBP = Diastolic blood pressure 
 
Table 2:  
Waist circumference and plasma levels of adiponectin and resistin in patients with schizophrenia, bipolar, depression and controls  
Parameters Schizophrenia 
(n = 35) 
Bipolar 
(n = 20) 
Depression 
(n = 10) 
Controls 










1866.87 (1126.22 – 
2485.35) 
2423.08 




Resistin (μg/l) 17.33 
(12.71 – 25.19) 
17.93 
(6.40 – 19.20) 
15.94 
(13.24 – 18.56) 
19.37 
(14.95 – 21.30) 
0.608 0.395 
*Significant at P<0.05, WC = Waist circumference,†P-value obtained after comparing the schizophrenia, bipolar and depression groups using Kruska Wallis, 
‡P-value obtained after comparing the schizophrenia, bipolar, depression and control groups using Kruskal Wallis, acompared with controls, bcompared with 
schizophrenia group. 
 
Table 3:  
Plasma levels of adiponectin and resistin based on adiposity and type of drugs 
 Adiponectin (mg/l) Resistin (μg/l) WC (cm) 
Central adiposity    
Normal adiposity (n = 29) 1422.37 (1139.11 – 2516.05) 16.76 (5.86 – 20.52) 77.04 ± 10.05 
Central obesity (n = 36) 1843.18 (1275.09 – 2532.66) 17.67 (14.27 – 21.11) 95.78 ± 9.63 
P-value 0.250 0.275 0.000* 
 
Type of drug 
   
Typical (n = 41) 1519.20 (1188.78 – 2593.70) 16.98 (13.13 – 19.59) 87.33 ± 13.98 
Atypical (n = 24) 1930.35 (1174.63 – 2599.98) 18.27 (13.85 – 21.24) 88.27 ± 13.54 
P-value 0.624 0.363 0.796 
 
Type of atypical drug 
   
Clozapine & Olanzapine (n = 13) 1896.24 (1269.89 – 2540.81) 17.33 (10.14 – 21.29) 91.85 ± 12.54 
Risperidone (n = 11) 2031.32 (1093.42 – 2637.92) 18.93 (17.37 – 22.84) 83.11 ± 13.97 
P-value 0.920 0.301 0.141 
*Significant at P<0.05, WC=Waist circumference 
 
 There was progressive increase in the median plasma 
adiponectin levels from schizophrenia, bipolar through 
depression. The median plasma adiponectin level was 
significantly higher in patients with depression compared with 
patients with schizophrenia and the controls (Table 2). Due to 
the association between central adiposity and adipokine 
production, the MMI group was divided into two subgroups 
viz; normal central adiposity (<80cm for female, <94cm for 
male) and central obesity (≥80cm for female, ≥94cm for 
male). The median plasma levels of adiponectin and resistin 
were insignificantly higher in patients with central obesity 
compared with patients without central obesity (Table 3). 
Similarly, the median plasma levels of adiponectin and resistin 
were insignificantly higher in patients on atypical drugs were 
compared with patients on typical drugs (Table 3). When 
patients on atypical drugs were subdivided into those on 
risperidone and those on clozapine or olanzapine, there was no 
significant difference in the median plasma levels of 
adiponectin and resistin when the 2 groups were compared 




Metabolic derangements continue to be a prominent feature of 
major mental illnesses (MMI). The observed elevation in 
anthropometric indices is not a novel finding. Earlier reports 
have shown that patients with MMI have increased of 
overweight and obesity, both central and peripheral 
(Dickerson et al., 2006, Simon et al., 2006, Saarni et al., 2009, 
Kivimaki et al., 2009). This has been attributed to the illness 
itself, binge eating, unhealthy lifestyle habits and treatment 
related factors (McElroy, 2009). These factors could also 
explain the observed elevation in blood pressure, albeit within 
the acceptable clinical cut-off, in patients with MMI. 
 Adiponectin is a circulating adipokine involved in anti-
inflammation, modulation of brain functions and sensitization 
of the body to insulin thereby playing a role in glucose and 
lipids metabolism (Une et al., 2011). The observed 
significantly elevated level of adiponectin in patients with 
MMI contradicts the reports of Cohn et al. (2006) and Beumer 
et al. (2012) but supports the reports of Song et al. (2013) and 
Bartoli et al. (2015). It has been shown that adiponectin 
inversely correlates with body mass index (BMI), body fat 
mass and visceral adiposity as larger adipocytes tend to 
produce lower level of adiponectin (Aprahamian and Sam, 
2011, Parida et al., 2019). This was not the case in this study 
as patients with MMI had elevated adiponectin level even with 
wider waist circumference (WC) and higher BMI than the 
controls. The observed elevation in adiponectin level might be 
a physiologic compensatory machinery through which the 
known metabolic effects of central and peripheral obesity are 
contained. This could also explain the observed significant 
elevation in adiponectin level in patients with depression, a 
group with wider WC, compared with patients with 
schizophrenia and controls thereby corroborating the report of 
Liu et al. (2012) which showed that adiponectin has 
antidepressant-like activity. An experimental study by Kim et 
al. (2007) revealed that increased expression of adiponectin 
Resistin and Adiponectin in Major Mental Illnesses 
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expands subcutaneous adipose tissue which causes resistance 
to the deleterious impact of high-fat diets on insulin sensitivity 
via increased expression of peroxisome proliferator-activated 
receptor gamma(PPAR-γ) target genes and reduction in 
adipose tissue infiltration by macrophages culminating in 
reduced systemic inflammation. However, caution is 
necessary in interpreting adiponectin level as its elevation is 
identified as an independent risk factor for the development of 
dementia and Alzheimer disease (van Himbergen et al., 2012). 
Furthermore, its elevation is associated with increased total 
pericardial fat mass and cardiomyopathy (Kim et al., 2007). 
The association between atypical antipsychotics and adverse 
metabolic events is well established although, the mechanisms 
involved are poorly understood (Richards et al., 2006, Savoy 
et al., 2010, Wang et al., 2013). Reports have shown that the 
type of atypical antipsychotics and the duration of usage could 
have differential effect on plasma adipokine level (Oriot et al., 
2008, Bai et al., 2009, Oral et al., 2011, Bartoli et al., 2015). 
The observed insignificant elevation in plasma adiponectin 
and resistin levels in patients on atypical drugs compared with 
patients on typical drugs and in those on clozapine and 
olanzapine compared with those on risperidone suggests that 
disordered adipokine level in patients with MMI involves 
several coordinated metabolic processes and not solely 
dependent on the type of drug used. This assumption is further 
buttressed by the observed similar levels of plasma 
adiponectin and resistin in patients with normal adiposity and 
central obesity despite the significant, but expected, 
differences in the WC of the two groups. Therefore, adipokine 
dysregulation might involve myriads of factors working 
synergistically and not central obesity and use of atypical 
antipsychotics alone. Further studies especially, with large 
population size, are suggested to substantiate findings from 
this study as small sample size was a limitation. Also, the 
baseline levels of adiponectin and resistin were not determined 
in patients with MMI before the commencement of 
antipsychotic medications.  
 It could be concluded from this study that patients with 
major mental illnesses have elevated level of adiponectin 
which does not appear to be influenced by the waist 
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